270,807 Shares in Kura Oncology, Inc. $KURA Purchased by OP Asset Management Ltd

OP Asset Management Ltd acquired a new position in shares of Kura Oncology, Inc. (NASDAQ:KURA) during the first quarter, Holdings Channel.com reports. The institutional investor acquired 270,807 shares of the company’s stock, valued at approximately $2,202,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in KURA. State Street Corp lifted its stake in Kura Oncology by 47.5% during the fourth quarter. State Street Corp now owns 4,931,090 shares of the company’s stock worth $51,234,000 after purchasing an additional 1,587,959 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its stake in shares of Kura Oncology by 101.6% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock valued at $19,688,000 after purchasing an additional 1,121,228 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Kura Oncology by 111.6% in the 4th quarter. Renaissance Technologies LLC now owns 1,830,566 shares of the company’s stock valued at $19,020,000 after purchasing an additional 965,256 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of Kura Oncology by 36.6% during the 4th quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock worth $31,816,000 after buying an additional 820,020 shares in the last quarter. Finally, Qube Research & Technologies Ltd raised its holdings in shares of Kura Oncology by 63.0% during the 2nd quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock worth $11,032,000 after buying an additional 738,761 shares in the last quarter.

Insider Activity

In other news, insider Mollie Leoni sold 84,929 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total value of $834,002.78. Following the completion of the transaction, the insider owned 182,345 shares of the company’s stock, valued at $1,790,627.90. This represents a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 7.60% of the stock is owned by corporate insiders.

Kura Oncology Stock Performance

Shares of KURA stock opened at $10.90 on Monday. Kura Oncology, Inc. has a twelve month low of $5.45 and a twelve month high of $12.49. The stock’s fifty day simple moving average is $9.57 and its 200 day simple moving average is $9.19. The company has a quick ratio of 6.14, a current ratio of 6.15 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $967.59 million, a P/E ratio of -3.25 and a beta of 0.36.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.05. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The firm had revenue of $18.27 million during the quarter, compared to the consensus estimate of $25.97 million. As a group, sell-side analysts predict that Kura Oncology, Inc. will post -3.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Mizuho reduced their price objective on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 24th. Wall Street Zen raised shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research note on Thursday, June 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a report on Tuesday, April 21st. Finally, Citizens Jmp reiterated a “market outperform” rating and set a $24.00 price objective on shares of Kura Oncology in a research report on Monday, June 15th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $25.46.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.